… the net clinical benefit (NCB) of a treatment on the patient. Radiation Therapy Oncology
Group (RTOG) trial 0525 hypothesized that using a dose-dense temozolomide regimen would …

… Forty-three patients affected with LGG (29 astrocytoma, four oligodendroglioma and 10
mixed oligo-astrocytoma) were treated with temozolomide (TMZ) at the time of documented …

… % of patients with glioblastoma derive no benefit from treatment with TMZ. For the treatment
of … Therefore, this study suggests that the benefit of adjuvant TMZ in the treatment of patients …

… importance that the clinical benefits of treatment are not offset by deterioration in HRQL as
a result of side effects of treatment. In this study, patients receiving temozolomide fared better, …

… This systematic review examines the role of temozolomide in patients with metastatic … a
benefit associated with the combination of temozolomide and interferon-α or thalidomide. …

… patients treated with temozolomide plus bevacizumab (N = 10), and 12.9 months in those
treated with temozolomide (… months in patients treated with temozolomide plus bevacizumab (N …

… health-related QOL benefits independent of steroid use. This study documents the efficacy,
safety, and QOL benefits of temozolomide in patients with recurrent anaplastic astrocytoma. …

… Among patients whose tumor contained a methylated MGMT promoter, a survival benefit
was observed in patients treated with temozolomide and radiotherapy; their median survival …

… in either disease, the drug has demonstrated clinically significant HR-QOL benefits when
compared … Temozolomide’s oral formulation allows patients to be treated in the home setting. …

… on archival tissue blocks from patients treated with temozolomide at the first recurrence. …
benefit in patients with 1p/19q intact AA/AOA treated with temozolomide at recurrence. …